When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...

Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One thing that stands out about Recursion right away is how the company refers to itself. Recursion doesn't say that it's a pharmaceutical, biopharmaceutical, or biotech company. Instead, it uses the ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer was focused on recently. A caller asked if the ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

The future of book adaptations is looking bright — and, well, a little terrifying. Hollywood is hungry for speculative epics imagining alternate realities grim enough to shake your faith in humanity.

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.